Kyverna Therapeutics, Inc.

Analysis for Ticker: KYTX

Kyverna Therapeutics Inc is a business that tries to fix the human body by reprogramming immune cells to fight severe autoimmune diseases like stiff person syndrome and lupus. While they chase these medical dreams, the actual financial reality is a machine that survives only by taking blood transfusions of cash from investors and spending it faster than it arrives. The math is a disaster because the company makes zero dollars from selling its science, yet it handed nearly 15$ million in total value to one man, Warner Biddle, in a single year. For a child to understand, imagine a lemonade stand that has no lemons and sells no lemonade, but the kids running it are buying themselves expensive toys using the money their parents gave them to buy supplies. The extraction of value started in the dark before most people even knew the company existed. In 2022, the business loaned 1,1$ million to its former chief executive, Peter Maag, so he could buy more shares. By 01/2024, the board simply decided he did not have to pay it back, forgiving the entire loan and all the interest. When they hired a new chief executive named Warner Biddle later in 2024, they handed him 650.000$ just for signing a piece of paper and another 172.426$ to pay for his moving truck and the taxes on that payment. By the end of 2024, Biddle's total pay package was valued at nearly 15$ million.